NERLYNX (neratinib)

SELF ADMINISTRATION

Indications for Prior Authorization:

  •  Kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2) over expressed/amplified breast cancer, to follow adjuvant Herceptin (trastuzumab infusion) based therapy

This medication is not approvable for the following condition(s):

  • Concurrent use of Nerlynx with other medications for adjuvant or neoadjuvant treatment of HER2-positive breast cancer

All of the following must be met as a condition for coverage:

  • Prescribed by an oncologist, AND
  • Patient has early-stage disease, AND
  • Women with HER2-positive breast cancer, AND
  • Completed 1 year of therapy with Herceptin, OR
  • Tried and intolerant to 1 year therapy with Herceptin

Dosing:

  • Recommended dose: 240 mg (6 tablets) orally once daily for 1 year
  • Hepatic Impairment (Child Pugh C): 80 mg (2 tablets) once daily

Approval:

  • One year

Last review date: September 4, 2018

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone